These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 22394224

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.
    Gunawardana M, Remedios-Chan M, Miller CS, Fanter R, Yang F, Marzinke MA, Hendrix CW, Beliveau M, Moss JA, Smith TJ, Baum MM.
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3913-9. PubMed ID: 25896688
    [Abstract] [Full Text] [Related]

  • 23. Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.
    Kashuba AD, Gengiah TN, Werner L, Yang KH, White NR, Karim QA, Abdool Karim SS.
    J Acquir Immune Defic Syndr; 2015 Jul 01; 69(3):264-9. PubMed ID: 26181703
    [Abstract] [Full Text] [Related]

  • 24. Impact of Tenofovir gel as a PrEP on HIV infection: a mathematical model.
    Rahman SM, Vaidya NK, Zou X.
    J Theor Biol; 2014 Apr 21; 347():151-9. PubMed ID: 24380779
    [Abstract] [Full Text] [Related]

  • 25. Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection.
    Gallant JE, Pham PA.
    Expert Rev Anti Infect Ther; 2003 Oct 21; 1(3):415-22. PubMed ID: 15482138
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.
    Karim SS, Kashuba AD, Werner L, Karim QA.
    Lancet; 2011 Jul 16; 378(9787):279-81. PubMed ID: 21763939
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
    Mirochnick M, Best BM, Stek AM, Capparelli EV, Hu C, Burchett SK, Rossi SS, Hawkins E, Basar M, Smith E, Read JS, IMPAACT 1026s Study Team.
    J Acquir Immune Defic Syndr; 2011 Apr 15; 56(5):412-9. PubMed ID: 21283017
    [Abstract] [Full Text] [Related]

  • 30. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.
    Kearney BP, Yale K, Shah J, Zhong L, Flaherty JF.
    Clin Pharmacokinet; 2006 Apr 15; 45(11):1115-24. PubMed ID: 17048975
    [Abstract] [Full Text] [Related]

  • 31. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention.
    van der Straten A, Van Damme L, Haberer JE, Bangsberg DR.
    AIDS; 2012 Apr 24; 26(7):F13-9. PubMed ID: 22333749
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.
    Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, Agot K, Lombaard J, Manongi R, Kapiga S, Kashuba A, Van Damme L, FEM-PrEP Study Group.
    J Acquir Immune Defic Syndr; 2014 Jul 01; 66(3):324-31. PubMed ID: 25157647
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
    Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Coombs RW, Hendrix C, Marzinke MA, Frenkel L, Haberer JE, Bangsberg D, Celum C, Partners PrEP Study Team.
    Lancet Infect Dis; 2014 Nov 01; 14(11):1055-1064. PubMed ID: 25300863
    [Abstract] [Full Text] [Related]

  • 36. Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherence.
    Blumenthal J, Haubrich R.
    Expert Opin Pharmacother; 2013 Sep 01; 14(13):1777-85. PubMed ID: 23800167
    [Abstract] [Full Text] [Related]

  • 37. Lack of a significant drug interaction between raltegravir and tenofovir.
    Wenning LA, Friedman EJ, Kost JT, Breidinger SA, Stek JE, Lasseter KC, Gottesdiener KM, Chen J, Teppler H, Wagner JA, Stone JA, Iwamoto M.
    Antimicrob Agents Chemother; 2008 Sep 01; 52(9):3253-8. PubMed ID: 18625763
    [Abstract] [Full Text] [Related]

  • 38. Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1.
    Herold BC, Dezzutti CS, Richardson BA, Marrazzo J, Mesquita PM, Carpenter C, Huber A, Louissaint N, Marzinke MA, Hillier SL, Hendrix CW.
    J Acquir Immune Defic Syndr; 2014 May 01; 66(1):65-73. PubMed ID: 24457633
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.